Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | BCHE | P06276 | 3/20 | 0.55 |
| ▸ | ACHE | P22303 | 3/20 | 0.55 |
| ▸ | BACE1 | P56817 | 3/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5102012 | 0.89 | SIGMAR1 (0.57) | MAPK1BCHEACHEBACE1SIGMAR1 | |
| SCHEMBL2101372 | 0.85 | POLB (0.42) | SIGMAR1RAB9AMEN1KMT2AHTT | |
| SCHEMBL5094770 | 0.77 | ACHE (0.57) | BCHEACHEBACE1SIGMAR1DPP7 | |
| SCHEMBL278631 | 0.75 | ACHE (0.62) | BCHEACHEBACE1SIGMAR1DPP7 | |
| SCHEMBL13327265 | 0.75 | MAPK1 (0.60) | MAPK1BCHEACHEBACE1SIGMAR1 | |
| SCHEMBL3960093 | 0.74 | SIGMAR1 (0.56) | BCHEACHEBACE1SIGMAR1DPP7 | |
| SCHEMBL2315603 | 0.74 | SIGMAR1 (0.60) | SIGMAR1TMEM97DPP7KMT2ADRD4 | |
| Hydrochloric Acid SCHEMBL9785794 | 0.74 | ACHE (0.60) | BCHEACHEBACE1SIGMAR1DPP7 | |
| Hydrochloric Acid SCHEMBL9785708 | 0.72 | ACHE (0.59) | BCHEACHEBACE1SIGMAR1DPP7 | |
| SCHEMBL3471796 | 0.72 | ACHE (0.59) | MAPK1BCHEACHEBACE1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013214-B1 | CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2015-06-24 | — | — | EP | disclosed |
| EP-2013214-A2 | CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2009-01-14 | — | — | EP | disclosed |
| US-7470680-B2 | Constrained compounds as CGRP-receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| WO-2007131020-A2 | CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-15 | — | — | WO | disclosed |
| US-20070259851-A1 | CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259851-A1 | CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS | CALCR, BDKRB2, CALCRL | MAPK1 1541/4885BCHE 1082/4885ACHE 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.